Design and Synthesis of Novel Arylisoxazole‐Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease

A novel series of hybrid arylisoxazole‐chromenone carboxamides were designed, synthesized, and evaluated for their cholinesterase (ChE) inhibitory activity based on the modified Ellman's method. Among synthesized compounds, 5‐(3‐nitrophenyl)‐ N ‐{4‐[(2‐oxo‐2 H ‐1‐benzopyran‐7‐yl)oxy]phenyl}‐1,2‐oxazole‐3‐carboxamide depicted the most acetylcholinesterase (AChE) inhibitory activity (IC 50 =1.23 μ m ) and 5‐(3‐chlorophenyl)‐ N ‐{4‐[(2‐oxo‐2 H ‐1‐benzopyran‐7‐yl)oxy]phenyl}‐1,2‐oxazole‐3‐carboxamide was found to be the most potent butyrylcholinesterase (BChE) inhibitor (IC 50 =9.71 μ m ). 5‐(3‐Nitrophenyl)‐ N ‐{4‐[(2‐oxo‐2 H ‐1‐benzopyran‐7‐yl)oxy]phenyl}‐1,2‐oxazole‐3‐carboxamide was further investigated for its BACE1 inhibitory activity as well as neuroprotectivity and metal chelating ability as important factors involved in onset and progress of Alzheimer's disease. It could inhibit BACE1 by 48.46 % at 50 μ m . It also showed 6.4 % protection at 25 μ m and satisfactory chelating ability toward Zn 2+ , Fe 2+ , and Cu 2+ ions. Docking studies of 5‐(3‐nitrophenyl)‐ N ‐{4‐[(2‐oxo‐2 H ‐1‐benzopyran‐7‐yl)oxy]phenyl}‐1,2‐oxazole‐3‐carboxamide and 5‐(3‐chlorophenyl)‐ N ‐{4‐[(2‐oxo‐2 H ‐1‐benzopyran‐7‐yl)oxy]phenyl}‐1,2‐oxazole‐3‐carboxamide confirmed desired interactions with those amino acid residues of the AChE and BChE, respectively.